John Reardon has joined Durham, NC-based Ribometrix as its chief scientific officer. Reardon was most recently head of research and development at HemoShear Therapeutics. His experience also includes posts at Revivo Therapeutics, Cadioxyl Pharmaceuticals, and GlaxoSmithKline (NYSE: [[ticker:GSK]]). Last November, Ribometrix closed a $30 million Series A round to finance development of small molecule drugs that target RNA involved in cancer and neurodegeneration.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
